35 results about "Eukaryotic translation" patented technology

A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I:or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.

A circular mRNA molecule possessing features resembling native mammalian mRNA demonstrates improved translation, while retaining the properties of an extremely long half-life inside cells. This circular mRNA is functional inside mammalian cells, being able to compete against native cellular mRNAs for the eukaryotic translation initiation machinery. The invention possesses additional RNA elements compared to a previous invention containing only an IRES element for successful in vitro or in vivo translation.

A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I:or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.

The invention belongs to the technical field of biology, and specifically relates to a 9R-eIF4A-VI fusion polypeptide and an application of fusion polypeptide in preparing a medicine for anti-depression. The studies confirm that PDCD4 can bind to a eukaryotic translation initiation factor (eIF4A) to inhibit the expression of a brain-derived neurotrophic factor (BDNF), impedes the repair and synaptic transmission of damaged neurons, and aggravates the symptoms of the depressed patients. The application screens a number of domains in which PDCD4 binds to eIF4A, by fusion of a transmembrane sequence and a domain on eIF4A, the fusion polypeptide having the interference effect is obtained, the experiments verify that the fusion polypeptide can effectively interfere with the binding of PDCD4 and eIF4A, has good transmembrane efficiency and stability, and can be applied to the preparation of antidepressant drugs, which has great significance.

The invention belongs to the technical field of photodynamic gene therapy, particularly relating to a photosensitizer binding protein and polypeptide and application thereof. In the invention, the photosensitizer binding protein is screened from a human liver cDNA (complementary Deoxyribonucleic Acid) phage display library. The binding protein is a human eukaryotic translation elongation factor (eEF1A1) protein and a protein molecule which is 70 to 80 percent similar to the protein in protein structure; the photosensitizer binding polypeptide is eEF1A1 C terminal 25aa and polypeptide which is70 to 80 percent similar to the 25aa in amino acid sequence. The photosensitizer binding protein can be bound with a porphyrin type photosensitizer in vitro and has an effect of enriching the porphyrin type photosensitizer in vivo; photosensitizer binding protein genes are transfected to various mammalian cells through adenoviruses, slow viruses or other modes; and a better photodynamic therapy effect is produced after artificial adjustment and control over inducible expression. In addition, the photosensitizer binding protein and polypeptide (PSP) provide a valuable reference for developing a photosensitizer prodrug and designing the specifically targeted photosensitizer.

Methods, compositions and kits for treating proliferative and non-proliferative diseases associated with abnormal protein synthesis. Chimeric peptide constructs are comprised in compositions and kits for use in the treatment of proliferative diseases, such as ovarian cancer, and for inhibiting protein synthesis in a tumor cell compared to a non-tumor cell.

The present application relates to papaya plants having increased resistance to the papaya ringspot virus as compared to a wild type plant due to a mutation in the eukaryotic translation initiation factor 4e and / or eukaryotic translation initiation factor iso4e gene leading to non-functional eukaryotic translation initiation factor 4e and / or eukaryotic translation initiation factor iso4e proteins. Methods of producing such papaya plants having increased resistance to the papaya ringspot virus are described.

Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to form rdsRNs de novo. The packaging strains and rdsRNs may also comprise nucleic acid sequences that stabilize a closed loop eukaryotic translation complex; nucleic acid sequences encoding one or more proteins that interfere with a host cell type I interferon (IFN) response; as well as recombinant alphavirus replicons encoding a protein complex specific for plus strand RNA-dependent synthesis of minus strand RNA

The invention provides a method for preparing a recombinant eukaryotic mRNA molecule by using a prokaryotic transcription system. The method comprises the following steps: 1) expressing an enzyme system required for the transcription and capping process of the recombinant eukaryotic mRNA, and obtaining a prokaryotic in-vitro transcription-capping enzyme system; 2) preparing a linear transcriptiontemplate DNA; and 3) transcribing, capping and purifying the recombinant mRNA. The recombinant mRNA molecule prepared by the method provided by the invention has all mRNA characteristics required by eukaryotic organisms in the protein translation process, so that the recombinant mRNA molecule can be further identified and utilized by a eukaryotic translation system. The method provided by the invention overcomes the defects in the field of recombinant mRNA at present, can produce the recombinant eukaryotic mRNA with stable genetic characteristics and no carrier inhibition effect in a simple process and at low cost, and meets the large-scale industrial production demand.

A screening method for identifying compounds that alter the fidelity with which the initiation codon in mRNAs is recognized by the translational apparatus in eukaryotes is disclosed. This screening method was used to identify compounds having such activity. Methods of altering the fidelity of initiation codon selection are also disclosed. Methods of treating disorders characterized by single nucleotide mutations in initiation codons using compounds identified by the screening method, as well as methods of treating fungal and parasitic infections and hyperproliferative disorders using compounds identified by the screening method are also disclosed.

This application is directed generally to minicircle DNA vectors for the vaccination of foot-and-mouth disease (FMD). The transgene expression cassette in the minicircle DNA vector includes: a eukaryotic translation initiation nucleotide sequence, a mutant nucleotide sequence that encodes a foot-and-mouth disease virus (FMDV) capsid polyprotein precursor that contains at least one mutation to eliminate a restriction enzyme recognition site, a nucleotide sequence that encodes a protease that cleaves the FMDV capsid polyprotein precursor into a plurality of FMDV capsid proteins and a translational regulatory element to regulate the expression of the protease. The minicircle DNA vectors can be transfected directly into the cell of a mammalian host. When transfected into the mammalian host cell, virus-like particles can be produced intrinsically to stimulate the mammalian host's immune system to develop adaptive immunity toward foot-and-mouth disease.

The present invention discloses applications of EIF4G1 in diagnosis of squamous cell carcinomas, particularly uses of a eukaryotic translation initiation factor 4G1 (EIF4G1) gene or protein, or a detection reagent thereof, wherein the eukaryotic translation initiation factor 4G1 (EIF4G1) gene or protein, or detection reagent thereof is used for preparing a kit for determining whether tumors are non-small cell lung squamous cell carcinomas. In addition, experiment results show that EIF4G1 has a certain high expression in squamous cell carcinomas with different sources, such that EIF4G1 can be adopted as the marker of the squamous cell carcinoma pathological type so as to provide the accurate method for typing of different sources of cancers.

A circular mRNA molecule possessing features resembling native mammalian mRNA demonstrates improved translation, while retaining the properties of an extremely long half-life inside cells. This circular mRNA is functional inside mammalian cells, being able to compete against native cellular mRNAs for the eukaryotic translation initiation machinery. The invention possesses additional RNA elements compared to a previous invention containing only an IRES element for successful in vitro or in vivo translation.

A screening method for identifying compounds that alter the fidelity with which the initiation codon in mRNAs is recognized by the translational apparatus in eukaryotes is disclosed. This screening method was used to identify compounds having such activity. Methods of altering the fidelity of initiation codon selection are also disclosed. Methods of treating disorders characterized by single nucleotide mutations in initiation codons using compounds identified by the screening method, as well as methods of treating fungal and parasitic infections and hyperproliferative disorders using compounds identified by the screening method are also disclosed.

Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and in vitro by a novel drugs mechanism of action described herein for pateamine A, including inhibition of eIF4A-dependent translation initiation. As with pateamine A, as described herein, suitable analogs cause cell cycle arrest or induce apoptosis in transformed cells. However, toxicity of such compounds to slow growing normal cells is low. In addition, such analogs, like pateamine A, target translation initiation factors and are useful as anticancer and antiproliferative agents in subjects in need thereof. Moreover, the analogs, like pateamine A, are valuable molecular probes for evalutaion of eukaryotic translation initiation and as lead compounds for development of improved anticancer agents.

Provided are an autoantibody specifically binding to an exosomal protein EIF3A (Eukaryotic translation initiation factor 3 subunit A) or a fragment including an antigen-binding site (paratope) thereof, a hybridoma cell line producing the autoantibody, a polypeptide having an amino acid sequence of an antigenic determinant (epitope) specifically binding to the autoantibody, a composition for diagnosing liver cancer including an agent measuring an expression level of the autoantibody or the fragment including the antigen-binding site thereof, a kit for diagnosing liver cancer including the composition, and a method of providing information for diagnosis of liver cancer by using the composition. Further, provided is a method of screening for a therapeutic agent for liver cancer by using an expression level of the autoantibody. When anti-EIF3A autoantibody of the present invention is used as a diagnostic marker for liver cancer, the incidence of liver cancer may be diagnosed at a high level only by using non-invasive biological samples. Furthermore, liver cancer may be easily diagnosed by using only the amino acid sequence identified in the present invention, leading to the effective development of diagnostic products such as a diagnostic kit for liver cancer.

The invention belongs to the technical field of biological detection, and particularly relates to a telomere length detection primer composition and a kit and application thereof. The kit provided by the invention comprises a primer composition for detecting a telomere repetitive sequence Tel, an interferon coding gene IFNB1, an eukaryotic translation elongation factor EEF1G, a peroxide oxidoreductase PRDX1, a ribosomal protein RPSA and / or a cytoskeleton protein VIM. The primer composition provided by the invention is used for detecting the telomere length, has better sensitivity, accuracy and repeatability, is high in amplification efficiency, simple and convenient to operate, rapid and time-saving, can be used for high-throughput screening and time monitoring, and has important practical significance for genetic and biological age evaluation of cancers and molecular epidemiological research.

The invention belongs to the technical field of photodynamic gene therapy, and specifically relates to a photosensitizer-binding protein and polypeptide and applications thereof. The invention screens a photosensitizer binding protein from a human liver cDNA phage display library. The binding protein is human eukaryotic translation elongation factor eEF1A1 protein and its protein molecule with 70%-80% similarity in protein structure, and the photosensitizer binding polypeptide is eEF1A1 C-terminal 25aa and its 70%-80% similar amino acid sequence. The photosensitizer-binding protein can be combined with porphyrin-type photosensitizers in vitro, and has the function of enriching porphyrin-type photosensitizers in vivo, and transfects the photosensitizer-binding protein gene into various Mammalian cells, after artificial regulation and induction of expression, have a better photodynamic therapy effect. In addition, the photosensitizer-binding protein and polypeptide (PSP) provides a valuable reference for the development of photosensitizer prodrugs and the design of specific targeted photosensitizers.

The invention discloses miRNA related to woody plant ammonium nitrogen response and application thereof, the miRNA comprises miRNA, the miRNA is miRNA (pc-miR166b) with up-regulated expression in a woody plant root system under an ammonium nitrogen treatment condition, a target gene of the miRNA is an eukaryotic translation initiation factor (eIF), the miRNA is highly expressed in an ammonium nitrogen treatment process, and by down-regulating the expression of the target gene, the response of the ammonium nitrogen in the woody plant can be reduced, so that the response of the ammonium nitrogen in the woody plant can be reduced, and the response of the ammonium nitrogen in the woody plant can be reduced. The miRNA (pc-miR166b) participates in the response process of the root system of the woody plant to the ammonium nitrogen, the miRNA (pc-miR166b) has good correlation with the response process of the root system of the woody plant to the ammonium nitrogen, and the effectiveness and molecular biology verification shows that the expression quantity of the pc-miR166b has obvious difference between the ammonium nitrogen treatment sample and the control group treatment sample; the method is of great significance to cultivation of novel woody plant germplasm capable of efficiently absorbing and utilizing soil nitrogen, and is suitable for popularization and application.

The invention discloses applications of eukaryotic translation elongation factors in the breast cancer detection reagent, wherein the eukaryotic translation elongation factors comprise the eukaryotic translation elongation factor 1delta and the eukaryotic translation elongation factor 2. The invention further discloses the reagent for detecting the genotype of the susceptible SNP site of the eukaryotic translation elongation factors, and a kit prepared by adopting the reagent. Through the development and applications of the SNP biomarker of the eukaryotic translation elongation factors and the diagnostic kit, the diagnosis for breast cancer is convenient and feasible, a foundation is laid for clinicians to rapidly know the disease conditions of patients, and for evaluating the clinical treatment effects, and assistance is offered for searching for novel micromolecular drug targets with the potential treatment value.

The present application relates to papaya plants having increased resistance to the papaya ringspot virus as compared to a wild type plant due to a mutation in the eukaryotic translation initiation factor 4e and / or eukaryotic translation initiation factor iso4e gene leading to non-functional eukaryotic translation initiation factor 4e and / or eukaryotic translation initiation factor iso4e proteins. Methods of producing such papaya plants having increased resistance to the papaya ringspot virus are described.

The present invention relates to a method of diagnosing Head and Neck Squamous Cell Carcinoma (HNSCC) in an individual. In addition, the present invention relates to a method of providing a survival prognosis to an individual suffering from Head and Neck Squamous Cell Carcinoma (HNSCC). Moreover, the present invention relates to a kit for performing the above-mentioned methods.

Provided are an autoantibody specifically binding to an exosomal protein EIF3A (Eukaryotic translation initiation factor 3 subunit A) or a fragment including an antigen-binding site (paratope) thereof, a hybridoma cell line producing the autoantibody, a polypeptide having an amino acid sequence of an antigenic determinant (epitope) specifically binding to the autoantibody, a composition for diagnosing liver cancer including an agent measuring an expression level of the autoantibody or the fragment including the antigen-binding site thereof, a kit for diagnosing liver cancer including the composition, and a method of providing information for diagnosis of liver cancer by using the composition. Further, provided is a method of screening for a therapeutic agent for liver cancer by using an expression level of the autoantibody. When anti-EIF3A autoantibody of the present invention is used as a diagnostic marker for liver cancer, the incidence of liver cancer may be diagnosed at a high level only by using non-invasive biological samples. Furthermore, liver cancer may be easily diagnosed by using only the amino acid sequence identified in the present invention, leading to the effective development of diagnostic products such as a diagnostic kit for liver cancer.

The invention relates to the technical field of a fluorescent quantitative PCR (polymerase chain reaction) detection method, in particular to a primer for detecting a mango EIF1A (eukaryotic translation initiation factor) gene and a real-time fluorescent quantitative PCR method. The method uses the fluorescent quantitative PCR technology for analyzing the EIFIA gene expression quantity of different tissues of the mango; the MiGAPDH is used as a reference gene; the reference gene primer and a target gene primer are designed; reverse transcription cDNA is used as a template for detecting the expression level of the target gene on Light 480. The detection result is subjected to statistical analysis; the expression and distribution condition of the EIF1A gene in different tissues of the mangocan be fast and accurately detected; the scientific basis is provided for cloning and utilizing the gene.

The invention belongs to the technical field of microorganisms, and particularly relates to a construction method of a monascus purpureus YJX-8 cDNA library and application of the library to screening of ester synthase LIP05 interaction protein. According to the construction method of the monascus purpureus YJX-8 cDNA library disclosed by the invention, LIP05 interaction proteins, namely cell nucleic acid binding proteins and eukaryotic translation initiation factors, are obtained by screening the library constructed according to the method, and expression of the LIP05 can be regulated and controlled on transcription and translation levels. The cDNA library constructed by the invention has an application prospect and a practical value for screening interaction proteins.

The invention discloses applications of eukaryotic translation elongation factors in the breast cancer detection reagent, wherein the eukaryotic translation elongation factors comprise the eukaryotic translation elongation factor 1delta and the eukaryotic translation elongation factor 2. The invention further discloses the reagent for detecting the genotype of the susceptible SNP site of the eukaryotic translation elongation factors, and a kit prepared by adopting the reagent. Through the development and applications of the SNP biomarker of the eukaryotic translation elongation factors and the diagnostic kit, the diagnosis for breast cancer is convenient and feasible, a foundation is laid for clinicians to rapidly know the disease conditions of patients, and for evaluating the clinical treatment effects, and assistance is offered for searching for novel micromolecular drug targets with the potential treatment value.

Provided are methods and compositions for inhibiting eukaryotic translation initiation factor. Such methods and compositions may be used alone or in conjunction with other therapies, such as gene therapies, for inhibiting cell proliferation and / or treating cancer.